We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.13B
AUM Growth
+$109M
Cap. Flow
-$57.7M
Cap. Flow %
-5.12%
Top 10 Hldgs %
41.36%
Holding
140
New
44
Increased
20
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$38.4M
2
LLY icon
Eli Lilly
LLY
+$37.9M
3
ONCR
Oncorus, Inc.
ONCR
+$20.9M
4
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$19.8M
5
CCCC icon
C4 Therapeutics
CCCC
+$12.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$56.2M
2
ABBV icon
AbbVie
ABBV
+$43.2M
3
AMGN icon
Amgen
AMGN
+$28M
4
FOLD
Amicus Therapeutics
FOLD
+$20M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 67.85%
2 Technology 8.78%
3 Industrials 3.15%
4 Consumer Discretionary 1.89%
5 Communication Services 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.02T
$69.2M 6.14%
410,000
+254,000
+163% +$37.9M
SRPT icon
2
CALL
Sarepta Therapeutics
SRPT
$1.57B
$63.1M 5.6%
370,000
+220,000
+147% +$32.6M
MRK icon
3
Merck
MRK
$322B
$59.6M 5.29%
763,791
-162,440
-18% -$12.4M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$53.2M 4.72%
338,200
-41,800
-11% -$6.17M
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$42.2M 3.75%
+300,000
New +$38.4M
NVS icon
6
Novartis
NVS
$297B
$40.5M 3.6%
429,000
+144,000
+51% +$12.6M
BMY icon
7
Bristol-Myers Squibb
BMY
$133B
$38.8M 3.44%
+625,000
New +$38.4M
ABBV icon
8
AbbVie
ABBV
$443B
$36.4M 3.23%
340,000
-450,000
-57% -$43.2M
AZN icon
9
AstraZeneca
AZN
$263B
$34.5M 3.06%
345,237
-64,763
-16% -$6.86M
ONCR
10
DELISTED
Oncorus, Inc.
ONCR
$28.4M 2.52%
+903,111
New +$20.9M
SGTX
11
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$26.1M 2.31%
+43,651
New +$19.8M
ABBV icon
12
CALL
AbbVie
ABBV
$443B
$24.1M 2.14%
225,000
+100,000
+80% +$9.61M
GNRC icon
13
Generac Holdings
GNRC
$11.6B
$24M 2.13%
105,663
+38,663
+58% +$8.32M
NICE icon
14
Nice
NICE
$5.79B
$21.1M 1.87%
74,481
+12,000
+19% +$2.92M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.69B
$16.6M 1.47%
745,900
+235,900
+46% +$4.89M
KURA icon
16
Kura Oncology
KURA
$800M
$15.4M 1.37%
471,494
+112,000
+31% +$3.94M
CCCC icon
17
C4 Therapeutics
CCCC
$385M
$14.6M 1.3%
+443,824
New +$12.9M
PANW icon
18
Palo Alto Networks
PANW
$270B
$13.5M 1.19%
+227,226
New +$10.6M
CERE
19
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$13.5M 1.19%
+811,665
New +$10.5M
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.57B
$12.8M 1.13%
75,000
-96,500
-56% -$14.3M
SRPT icon
21
PUT
Sarepta Therapeutics
SRPT
$1.57B
$12.8M 1.13%
75,000
-75,000
-50% -$11.1M
AUDC icon
22
AudioCodes
AUDC
$244M
$11.8M 1.05%
+428,971
New +$12.6M
ZYME icon
23
Zymeworks
ZYME
$1.61B
$11.6M 1.03%
245,000
+165,000
+206% +$7.66M
ALXO icon
24
ALX Oncology
ALXO
$261M
$11.5M 1.02%
133,448
-48,622
-27% -$2.92M
KRNT icon
25
Kornit Digital
KRNT
$705M
$11.4M 1.02%
128,381
-15,000
-10% -$1.15M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sphera Funds Management held 140 positions worth $1.13B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $57.7M in Q4 2020, closing 30 positions and reducing 33 holdings. Its most notable exit was Sanofi, an estimated $56.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Bristol-Myers Squibb worth $38.8M.

  • Sphera Funds Management's largest Q4 2020 buy was Bristol-Myers Squibb: 625,000 shares worth $38.8M.
  • Sphera Funds Management added most to Eli Lilly in Q4 2020, an estimated $37.9M increase.
  • Sphera Funds Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $43.2M.
  • Sphera Funds Management fully exited Sanofi in Q4 2020, selling an estimated $56.2M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.13B portfolio in Q4 2020.
  • Sphera Funds Management opened 44 new positions and closed 30 in Q4 2020.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $1.13B.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.